Suzetrigine: A First-in-class NaV1.8 Inhibitor for Opioid-free Pain Management

Background: Opioids have been an integral part of pain management for many years. With the increasing global burden of opioid dependence, the development of non-opioid therapies provides a new framework for pain management. Suzetrigine is a stepping stone toward non-opioid treatment methods. Objectives: To summarize the pharmacological profile, preclinical and clinical trial evidence of suzetrigine in opioid-free pain management. Materials and Methods: Published research, clinical trial data, and review articles from PubMed, Cochrane, and Google Scholar were reviewed from January to July 2025. The findings have been consolidated in this article to summarize them in relation to suzetrigine to provide an overview from pharmacological and clinical perspectives. Results: In vitro and in vivo studies demonstrated the voltage-gated sodium channel, NaV1.8, selective property of the drug. Vertex Pharmaceuticals has conducted four randomized controlled trials (two Phase 2 and two Phase 3 [NAVIGATE-1 and NAVIGATE-2]) and one open-label trial to assess the efficacy and safety profile of suzetrigine. Significant pain reduction was observed with suzetrigine compared to that with placebo. Nausea was the most common adverse effect observed with the drug; however, the drug was otherwise well tolerated and showed low abuse potential. The United States Food and Drug Administration approved suzetrigine for the treatment of moderate to severe acute pain on January 30, 2025. Several trials for the application of the drug in the management of chronic pain are ongoing, among which some have reported promising results. This review summarizes the pharmacological profile of suzetrigine, its future perspectives, current trends, and potential changes in pain management. Conclusion: Suzetrigine is a first-in-class non-opioid analgesic and NaV1.8 inhibitor, approved only for the treatment of moderate to severe acute pain. With a less addictive nature and good safety profile, its potential in the management of conditions with chronic pain is yet to be elucidated from clinical trials with a long-term follow-up period.